FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952207847> ?p ?o ?g. }

• W2952207847 endingPage "7" @default.
• W2952207847 startingPage "6" @default.
• W2952207847 abstract "Background: Eradication of minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL) may be necessary for deep and durable responses. Aims: To assess the safety, pharmacokinetics, and efficacy of lisocabtagene maraleucel (liso-cel, JCAR017), an investigational, anti-CD19 chimeric antigen receptor (CAR) T cell product administered as a defined composition of CD4+/CD8+ CAR T cells, in the ongoing phase 1/2 TRANSCEND CLL 004 study. Methods: Eligible patients had CLL or small lymphocytic lymphoma (SLL), had received ≥2 prior lines of therapy (including Bruton's tyrosine kinase inhibitors [BTKi] unless medically contraindicated), and had an Eastern Cooperative Oncology Group performance status of ≤1. After 3 days of lymphodepleting chemotherapy, patients received liso-cel infusion at either dose level 1 (50 × 106) or dose level 2 (100 × 106) total CAR+ T cells. Patients were monitored for dose-limiting toxicities. Response was assessed by International Workshop on CLL 2008 criteria. MRD was assessed by flow cytometry in blood (sensitivity, 10−4) and by Next-Generation Sequencing in bone marrow (BM; sensitivity, 10−6). Results: At data cutoff, 16 patients received liso-cel: n = 6 in dose level 1 and n = 10 in dose level 2. Of the patients, 75% had high-risk features (TP53 mutation, complex karyotype, or del17p); 100% had received prior ibrutinib and 50% had received prior venetoclax. Median (range) number of prior lines of therapy was 4.5 (2-11). There was 1 dose-limiting toxicity of grade 4 hypertension at dose level 2. The most common grade 3/4 treatment-emergent adverse events were cytopenias (thrombocytopenia, 75%; anemia, 69%; neutropenia, 63%; leukopenia, 56%). One patient had grade 3 cytokine release syndrome (CRS); 3 patients had grade 3 neurological events (NE). Best overall response rate (ORR) in 15 evaluable patients was 87% (13/15). Seven patients (47%) achieved complete remission with/without complete blood count recovery (CR/CRi). ORR at 6 mo was 83% (5/6). Undetectable MRD (uMRD) in blood was achieved in 10/15 patients (67%) by day 30, and in BM in 7/8 patients (88%). MRD-negative CRs were seen in patients who had failed both BTKi and venetoclax. Median (range) time to peak blood CAR+ T cell level was 16 (4–30) days. Summary/Conclusion: In this study of heavily pretreated patients with standard- and high-risk CLL/SLL and previous ibrutinib treatment, liso-cel-related toxicities (ie, CRS and NEs) were manageable. Patients rapidly achieved CR/CRi and uMRD. The phase 2 component of the study is currently enrolling patients for treatment at dose level 2. Additional follow-up will be presented." @default.
• W2952207847 created "2019-06-27" @default.
• W2952207847 creator A5005565037 @default.
• W2952207847 creator A5027765136 @default.
• W2952207847 creator A5030806657 @default.
• W2952207847 creator A5031412066 @default.
• W2952207847 creator A5036343829 @default.
• W2952207847 creator A5056327118 @default.
• W2952207847 creator A5067931142 @default.
• W2952207847 creator A5071991576 @default.
• W2952207847 creator A5088343926 @default.
• W2952207847 creator A5089428686 @default.
• W2952207847 date "2019-06-01" @default.
• W2952207847 modified "2023-10-16" @default.
• W2952207847 title "S109 TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE NEGATIVE RESPONSES AFTER LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA" @default.
• W2952207847 doi "https://doi.org/10.1097/01.hs9.0000558656.85709.c7" @default.
• W2952207847 hasPublicationYear "2019" @default.
• W2952207847 type Work @default.
• W2952207847 sameAs 2952207847 @default.
• W2952207847 citedByCount "0" @default.
• W2952207847 crossrefType "journal-article" @default.
• W2952207847 hasAuthorship W2952207847A5005565037 @default.
• W2952207847 hasAuthorship W2952207847A5027765136 @default.
• W2952207847 hasAuthorship W2952207847A5030806657 @default.
• W2952207847 hasAuthorship W2952207847A5031412066 @default.
• W2952207847 hasAuthorship W2952207847A5036343829 @default.
• W2952207847 hasAuthorship W2952207847A5056327118 @default.
• W2952207847 hasAuthorship W2952207847A5067931142 @default.
• W2952207847 hasAuthorship W2952207847A5071991576 @default.
• W2952207847 hasAuthorship W2952207847A5088343926 @default.
• W2952207847 hasAuthorship W2952207847A5089428686 @default.
• W2952207847 hasBestOaLocation W29522078471 @default.
• W2952207847 hasConcept C126322002 @default.
• W2952207847 hasConcept C143998085 @default.
• W2952207847 hasConcept C2776694085 @default.
• W2952207847 hasConcept C2776755627 @default.
• W2952207847 hasConcept C2777609679 @default.
• W2952207847 hasConcept C2777938653 @default.
• W2952207847 hasConcept C2778461978 @default.
• W2952207847 hasConcept C2779263901 @default.
• W2952207847 hasConcept C2779338263 @default.
• W2952207847 hasConcept C2779823535 @default.
• W2952207847 hasConcept C2779878957 @default.
• W2952207847 hasConcept C71924100 @default.
• W2952207847 hasConcept C90924648 @default.
• W2952207847 hasConceptScore W2952207847C126322002 @default.
• W2952207847 hasConceptScore W2952207847C143998085 @default.
• W2952207847 hasConceptScore W2952207847C2776694085 @default.
• W2952207847 hasConceptScore W2952207847C2776755627 @default.
• W2952207847 hasConceptScore W2952207847C2777609679 @default.
• W2952207847 hasConceptScore W2952207847C2777938653 @default.
• W2952207847 hasConceptScore W2952207847C2778461978 @default.
• W2952207847 hasConceptScore W2952207847C2779263901 @default.
• W2952207847 hasConceptScore W2952207847C2779338263 @default.
• W2952207847 hasConceptScore W2952207847C2779823535 @default.
• W2952207847 hasConceptScore W2952207847C2779878957 @default.
• W2952207847 hasConceptScore W2952207847C71924100 @default.
• W2952207847 hasConceptScore W2952207847C90924648 @default.
• W2952207847 hasIssue "S1" @default.
• W2952207847 hasLocation W29522078471 @default.
• W2952207847 hasLocation W29522078472 @default.
• W2952207847 hasOpenAccess W2952207847 @default.
• W2952207847 hasPrimaryLocation W29522078471 @default.
• W2952207847 hasRelatedWork W2204827588 @default.
• W2952207847 hasRelatedWork W2754654824 @default.
• W2952207847 hasRelatedWork W2794302045 @default.
• W2952207847 hasRelatedWork W2958355556 @default.
• W2952207847 hasRelatedWork W2980870211 @default.
• W2952207847 hasRelatedWork W3014972780 @default.
• W2952207847 hasRelatedWork W3029558579 @default.
• W2952207847 hasRelatedWork W3094956472 @default.
• W2952207847 hasRelatedWork W3160469825 @default.
• W2952207847 hasRelatedWork W4309787431 @default.
• W2952207847 hasVolume "3" @default.
• W2952207847 isParatext "false" @default.
• W2952207847 isRetracted "false" @default.
• W2952207847 magId "2952207847" @default.
• W2952207847 workType "article" @default.